Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen in Patients With Established Cardiovascular Disease and Elevated Lp(a)
NCT04023552Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2019
- Primary completion
- Jul 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 43
01
Overview
A Phase 3 trial of pelacarsen in cardiovascular disease (CVD), sponsored by Novartis. Started Dec 2019; status: completed.
02
Drugs
pelacarsen
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT04023552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023552.